[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573223":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":29,"responsibleParty":60,"collaborators":63,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":10,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Leiden University Medical Center","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"MG patients",null,"MG patients with at least one of the symptoms of interest (i.e. dysarthria, dysphonia, proximal arm fatigue and\u002For ptosis). We aim to include 150 patients with Myasthenia Gravis.",{"label":13,"type":10,"description":14,"interventionNames":10},"Non-MG participants","Non-MG participants that do not have a medical history of any of the symptoms of interest. We aim to include 75 controls.",[16],{"name":17,"affiliation":5,"role":18},"Martijn R. Tannemaat, MD, PhD","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Martijn R Tannemaat, MD, PhD","CONTACT","+31715262197","m.r.tannemaat@lumc.nl",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Yvonne JM Campman, MD","+31715262118","y.j.m.campman@lumc.nl",[30,52],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"NOT_YET_RECRUITING","Leiden","South Holland","2333 ZA","Netherlands","NL",{"type":38,"coordinates":39},"Point",[40,41],4.49306,52.15833,{"lat":41,"lon":40},[44,46,47,48,50],{"name":45,"role":22,"phone":23,"phoneExt":10,"email":24},"Martijn R Tannemaat, MD PhD",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},{"name":45,"role":18,"phone":10,"phoneExt":10,"email":10},{"name":26,"role":49,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":51,"role":49,"phone":10,"phoneExt":10,"email":10},"Jan JGM Verschuuren, MD PhD",{"facility":5,"status":53,"city":32,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"RECRUITING",{"type":38,"coordinates":55},[40,41],{"lat":41,"lon":40},[58,59],{"name":21,"role":22,"phone":27,"phoneExt":10,"email":24},{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},{"type":18,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Martijn R. Tannemaat, MD PhD","Principal investigator",[64],{"name":65,"class":66},"Huma","INDUSTRY","100573223","capturing-key-mg-symptoms-using-smartphone-recordings-100573223",false,"NCT06743490","Capturing Key MG-symptoms Using Smartphone Recordings.","Capturing Key Symptoms Using Smartphone Recordings in Patients With Myasthenia Gravis (CAPTURE-MG)","CAPTURE - MG","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to understand the requirements of the study and provide written informed consent.\n\nInclusion Criteria for MG participants only:\n\n1. A clinical diagnosis of myasthenia gravis (ocular or generalized) as defined by the Dutch national guideline (category \"definite\" or \"probable\" MG).\n2. MGFA Clinical Classification of disease severity I-IV.\n3. Subjects have at least one of the symptoms of interest (namely dysarthria, dysphonia, proximal arm fatigue and\u002For ptosis).\n\nInclusion Criteria for non-MG participants only\n\n1. Subjects are not diagnosed with and have no clinical suspicion of MG.\n2. Subjects do not have a medical history of any of the symptoms of interest (namely dysarthria, dysphonia, proximal arm fatigue and\u002For ptosis).\n\nExclusion Criteria:\n\n1. Not willing to be audio-recorded for the study assessments.\n2. Not willing to be video-recorded for the study assessments.\n3. Subjects currently taking part in a clinical trial of an Investigational Medicinal Product.\n4. Subjects who have used an immediate release pyridostigmine-based medication in the 12 hours prior to their participation and participants on prolonged release pyridostigmine.\n5. Subjects have cognitive or physical limitations that, in the opinion of the investigator, limits the subject's ability to complete study procedures\u002F\n\nExclusion Criteria for MG participants only:\n\n1. Subjects with an upper-limb amputation or who are non-verbal.\n2. Subjects with a diagnosed neurological disease resulting in muscle weakness, other than MG.\n\nExclusion Criteria for non-MG participants only:\n\n1\\. Limitation of upper limb mobility or speech impairment of any cause.",true,"ALL","18 Years",{"count":79,"type":80},225,"ESTIMATED","OBSERVATIONAL","This study will make use of a cross-sectional design of MG patients and non-MG participants to quantitatively assess key MG symptoms, and to explore the applicability of machine learning algorithms to their measurement.",[84,85],"Myasthenia Gravis","Fatigue",[84,85,87,88,89,90,91,92],"Digital features","Machine Learning Algorithms","Dysarthria","Dysphonia","Proximal arm fatigue","Ptosis","2025-09-02",{"date":95,"type":96},"2025-09-09","ACTUAL",{"date":98,"type":96},"2025-03-18",{"date":100,"type":80},"2026-04-01",{"name":5,"class":6},2]